Surgical Management of Obesity in Brazil: Proposal for a Value-Based Healthcare Model and Preliminary Results.

OBJECTIVES: To describe the implementation and 1-year results of a value-based bariatric surgery program in Brazil. METHODS: The study was conducted at a private hospital in São Paulo, Brazil (Hospital Alemão Oswaldo Cruz). A value-based healthcare program was implemented by designing an episode of care for eligible patients and developing a bundled payment model in which a single payment was made for the bariatric surgery covering the preoperative workup and ending 30 days after discharge. Assessment of outcomes included complication rate, hospital length of stay, intensive care admissions, reoperations, readmissions, and visits to the emergency department in the 30-day postoperative period. The results were compared with real-world evidence retrieved from a Brazilian private insurance database containing information on bariatric procedures performed in similar institutions (benchmark group). RESULTS: Eighty-three patients were enrolled in the value-based healthcare program (80.7% women; 18.0% with type 2 diabetes mellitus; 31.0% with high blood pressure). The mean age was 40.9 years, and body mass index was 42.1 kg/m2. The outcomes recorded in the benchmark group versus the value-based healthcare group involved complication rate, 2.6% versus 1.4% (P = 0.69); length of stay, 2.5 versus 2.0 days (P = 0.0001); intensive care admissions, 4.0% versus 1.2% (P = 0.31); emergency care visits, 15.0% versus 6.0% (P = 0.04); and readmissions, 2.3% versus 0 (P = 0.35), with an estimated cost reduction of 7.1%. CONCLUSIONS: These initial results showed favorable surgical and 30-day outcomes, demonstrating the benefits of a value-based approach for the surgical management of obesity and its comorbidities.

Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older.

OBJECTIVES: To systematically review the economic evaluations of 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults aged ≥60 years to inform the development of local studies through the discussion of parameters and assumptions that influence the results of the analyses. METHODS: We searched the MEDLINE, Excerpta Medica, Cochrane Library, Latin-American and Caribbean Health Sciences Literature (LILACS), Brazilian Regional Library of Medicine, National Health Service Economic Evaluation, and Centre for Reviews and Dissemination-as well as the Scopus citation index and the Web of Science for full economic evaluations of PPV23 published up to March 2016. Two independent reviewers screened the articles for relevance and extracted the data. Main study characteristics and methods (clinical and epidemiological data, cost and incremental cost-effectiveness ratios (ICERs) were extracted and compared. Costs were updated to 2016 international dollars. RESULTS: Twenty-seven studies published from 1980 to 2016 were reviewed. Most studies were conducted in Europe and the USA; three studies were conducted in Latin America (Brazil, 2; Colombia, 1). In addition to the scenario comparing the vaccination with the PPV23 to non-vaccination, three studies also compared PPV23 to pneumococcal conjugate 13-valent vaccine (PCV13). All studies used static models. Most used a lifetime (44.4%) or 5-6 year's time horizon (33.3%). Only three studies considered herd protection from children immunization with PCV13 in the model. Most studies considered PPV23 cost-effective (less than US$50,000 per LYG or QALY) and sometimes cost-saving (results ranging from cost-saving to US$84,636/QALY). The estimates of disease burden, the efficacy/effectiveness of PPV23, and the effects of herd protection from childhood immunization had most influence on the results. CONCLUSIONS: Well-designed cost-effectiveness studies of PPV23 that represent the current epidemiological scenario and reduce uncertainty related to efficacy/effectiveness are extremely relevant to informing the decision-making process.

Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.

OBJECTIVE: To evaluate the cost-effectiveness of introducing universal vaccination of adults aged 60 years with the 23-valent pneumococcal polysaccharide vaccine (PPV23) into the National Immunization Program (NIP) in Brazil. METHODS: Economic evaluation using a Markov model to compare two strategies: (1) universal vaccination of adults aged 60 years with one dose of PPV23 and 2) current practice (vaccination of institutionalized elderly and elderly with underlying diseases). The perspective was from the health system and society. Temporal horizon was 10 years. Discount rate of 5% was applied to costs and benefits. Clinical syndromes of interest were invasive pneumococcal disease (IPD) including meningitis, sepsis and others and pneumonia. Vaccine efficacy against IPD was obtained from a meta-analysis of randomized control trials and randomized studies, whereas vaccine effectiveness against pneumonia was obtained from cohort studies. Resource utilization and costs were obtained from the Brazilian Health Information Systems. The primary outcome was cost per life year saved (LYS). Univariate and multivariate sensitivity analysis were performed. RESULTS: The universal vaccination strategy avoided 7,810 hospitalizations and 514 deaths, saving 3,787 years of life and costing a total of USD$31,507,012 and USD$44,548,180, respectively, from the health system and societal perspective. The universal immunization would result in ICERs of USD$1,297 per LYS, from the perspective of the health system, and USD$904 per LYS, from the societal perspective. CONCLUSION: The results suggest that universal vaccination of adults aged 60 years with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is a very cost-effective intervention for preventing hospitalization and deaths for IPD and pneumonia is this age group in Brazil.

Decision tree cnnstruction and cost-effectivenes analysis of treatment of ulceerative colitis with pentasa® mesalazine 2 g sachet / Construcao de arvore de decisao e analise de custo-efetividade do tratamento da retocolite ulcerativa com Pentasa (mesalazina) 2 g sache

Context Unspecified Ulcerative Rectocolitis is a chronic disease that affects between 0.5 and 24.5/105 inhabitants in the world. National and international clinical guidelines recommend the use of aminosalicylates (including mesalazine) as first-line therapy for induction of remission of unspecified ulcerative rectocolitis, and recommend the maintenance of these agents after remission is achieved. However, multiple daily doses required for the maintenance of disease remission compromise compliance with treatment, which is very low (between 45% and 65%). Use of mesalazina in granules (2 g sachet) once daily - Pentasa® sachets 2 g - can enhance treatment adherence, reflecting in an improvement in patients' outcomes. Objective To evaluate the evidence on the use of mesalazine for the maintenance of remission in patients with unspecified ulcerative rectocolitis and its effectiveness when taken once versus more than once a day. From an economic standpoint, to analyze the impact of the adoption of this dosage in Brazil's public health system, considering patients' adherence to treatment. Methods A decision tree was developed based on the Clinical Protocol and Therapeutic Guidelines for Ulcerative Colitis, published by the Ministry of Health in the lobby SAS/MS n° 861 of November 4 th, 2002 and on the algorithms published by the Associação Brasileira de Colite Ulcerativa e Doença de Crohn, aiming to get the cost-effectiveness of mesalazine once daily in granules compared with mesalazine twice daily in tablets. Results The use of mesalazine increases the chances of remission induction and maintenance when compared to placebo, and higher doses are associated with greater chance of success without increasing the risk of adverse events. Conclusion The use of a single daily dose in the maintenance of remission is effective and related to higher patient compliance when compared to the multiple daily dose regimens, ...

Contexto A retocolite ulcerativa inespecífica é uma doença crônica que atinge entre 0,5 e 24,5/105 habitantes no mundo. Diretrizes clínicas nacionais e internacionais recomendam o emprego de aminosalicilatos (entre eles, a mesalazina) como terapia de primeira linha na indução da remissão da retocolite ulcerativa inespecífica, com manutenção destes agentes após a remissão. Mas as múltiplas doses diárias necessárias comprometem a adesão ao tratamento, que é muito baixa (entre 45% e 65%). A utilização de mesalazina em grânulos (sachê 2 g) dose única diária - Pentasa® sachê 2 g - pode aumentar a aderência ao tratamento, refletindo numa melhora nos desfechos dos pacientes. Objetivo Avaliar as evidências sobre o uso de mesalazina para a manutenção da remissão em pacientes com retocolite ulcerativa inespecífica e sua eficácia quando tomada uma vez versus mais de uma vez ao dia. Do ponto de vista econômico, avaliar o impacto que a adoção desta posologia teria para o sistema público de saúde do país, comparada ao tratamento padrão atual, considerando a adesão dos pacientes. Métodos Foi elaborada uma árvore de decisão construída a partir do Protocolo Clínico e Diretrizes Terapêuticas de Colite Ulcerativa, publicado pelo Ministério da Saúde na portaria SAS/MS n° 861, de 04 de novembro de 2002, e de algoritmos publicados pela Associação Brasileira de Colite Ulcerativa e Doença de Crohn, objetivando-se obter o custo-efetividade da mesalazina dose única diária em grânulos comparado com mesalazina duas vezes ao dia em comprimidos. Resultados O emprego de mesalazina aumenta as chances de indução da remissão e sua manutenção, quando comparado a ...

Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.

CONTEXT: Unspecified Ulcerative Rectocolitis is a chronic disease that affects between 0.5 and 24.5/105 inhabitants in the world. National and international clinical guidelines recommend the use of aminosalicylates (including mesalazine) as first-line therapy for induction of remission of unspecified ulcerative rectocolitis, and recommend the maintenance of these agents after remission is achieved. However, multiple daily doses required for the maintenance of disease remission compromise compliance with treatment, which is very low (between 45% and 65%). Use of mesalazina in granules (2 g sachet) once daily--Pentasa® sachets 2 g--can enhance treatment adherence, reflecting in an improvement in patients' outcomes. OBJECTIVE: To evaluate the evidence on the use of mesalazine for the maintenance of remission in patients with unspecified ulcerative rectocolitis and its effectiveness when taken once versus more than once a day. From an economic standpoint, to analyze the impact of the adoption of this dosage in Brazil's public health system, considering patients' adherence to treatment. METHODS: A decision tree was developed based on the Clinical Protocol and Therapeutic Guidelines for Ulcerative Colitis, published by the Ministry of Health in the lobby SAS/MS n° 861 of November 4 th, 2002 and on the algorithms published by the Associação Brasileira de Colite Ulcerativa e Doença de Crohn, aiming to get the cost-effectiveness of mesalazine once daily in granules compared with mesalazine twice daily in tablets. RESULTS: The use of mesalazine increases the chances of remission induction and maintenance when compared to placebo, and higher doses are associated with greater chance of success without increasing the risk of adverse events. CONCLUSION: The use of a single daily dose in the maintenance of remission is effective and related to higher patient compliance when compared to the multiple daily dose regimens, with lower costs.

Implante por cateter de bioprótese valvular aórtica para tratamento de estenose valvar aórtica grave em pacientes inoperáveis sob perspectiva da saúde suplementar: análise de custo-efetividade / Transcatheter aortic valve implantation for the treatment of severe aortic valve stenosis in inoperable patients under the perspective of the brazilian supplemental health system: cost-effectiveness analysis

INTRODUÇÃO: O implante por cateter de bioprótese valvular aórtica (TAVI, do inglês transcatheter aortic valve implantation) constitui nova modalidade de tratamento destinada, sobretudo, aos pacientes com elevado risco cirúrgico. Para esses pacientes, o TAVI resultou em aumento da sobrevivência e melhora da qualidade de vida, comparativamente ao tratamento padrão (medicamentoso, com ou sem valvuloplastia aórtica percutânea). Nosso objetivo foi realizar análise de custo-efetividade da implementação do TAVI no Sistema de Saúde Suplementar brasileiro. MÉTODOS: Foram desenvolvidos um modelo preditivo, para avaliar custo-efetividade real do procedimento em longo prazo, e uma regressão de Weibull com tempo horizonte de 5 e 10 anos, para estimar dados de sobrevida por mais de 24 meses. Adicionalmente, foi desenvolvido modelo de Markov sequencial e determinístico. Resultados foram expressos como razão de custo-efetividade incremental (RCEI) por anos de vida ganhos e anos de vida livres de progressão. RESULTADOS: Para o cenário padrão, no qual o custo da TAVI foi estipulado em R$ 65 mil, o valor da RCEI (custo/ano de vida salvo) em 5 anos foi de R$ 72.520,65. Alterando-se o tempo horizonte para 10 anos, esse valor diminuiu para R$ 41.653,01. CONCLUSÕES: O modelo apontou que o TAVI apresenta efetividade superior e maior custo incremental. Além disso, a incorporação do TAVI no Rol de Procedimentos e Eventos em Saúde da Agência Nacional de Saúde Suplementar acarretaria impacto orçamentário incremental nos próximos 5 anos, variando de R$ 70 milhões a R$ 121 milhões, compatível com o de outras tecnologias já incorporadas no âmbito da Saúde Suplementar.

BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a new modality of treatment especially dedicated to patients with high surgical risk. In these patients, TAVI increased survival and improved quality of life when compared to standard treatment (drug therapy with or without percutaneous aortic balloon valvuloplasty). Our objective was to perform a cost-efficacy analysis of the implementation of TAVI in the Brazilian Supplemental Health System. METHODS: We developed a predictive model to assess the cost-effectiveness of the procedure in the long-term, and a Weibull regression analysis with a time horizon of 5 and 10 years, to estimate survival data for over 24 months. In addition, a deterministic sequential Markov model was developed. Results were expressed as incremental cost-effectiveness ratio (ICER) per years of life saved and progression-free years of life. RESULTS: In a standard scenario, where the cost of TAVI was estimated as R$ 65 millions, the ICER value (cost/year of life saved) in 5 years was R$ 72,520.65. When the time horizon was adjusted for 10 years, this amount decreased to R$ 41,653.01. CONCLUSIONS: The model indicated that TAVI has superior effectiveness and higher incremental cost. Furthermore, the incorporation of TAVI in the List of Health Procedures and Events of the Brazilian Supplemental Health System would have an incremental budgetary impact over the next 5 years, ranging from R$ 70 millions to R$ 121 millions, consistent with other technologies which have already been incorporated by the system.